Covid-19 roundup: FDA formally hands Pfizer/BioNTech's vaccine a priority review; European regulators look to Kineret to treat at-risk patients
The FDA said last Friday that it would give an expedited look at the Pfizer-BioNTech vaccine for full approval in patients ages 16 and older …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
